Sex-dependent psychoneuroendocrine effects of THC and MDMA in an animal model of adolescent drug consumption

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Llorente Berzal, Alvaro ^a,b   Puighermanal, Emma ^c   Burokas, Aurelijus ^c   Ozaita, Andrés ^c   Maldonado, Rafael ^c   Marco, Eva M ^a,b   Viveros, Maria Paz ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACTIVITY REGULATED CYTOSKELETON ASSOCIATED PROTEIN; CORTICOSTERONE; LEPTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OREXIN; PREPROOREXIN; PROTEIN PRECURSOR; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG UTILIZATION; ELEVATED PLUS MAZE TEST; EXPERIMENTAL MODEL; EXPLORATORY BEHAVIOR; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS; IMMUNOREACTIVITY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREPULSE INHIBITION; PREPULSE INHIBITION DISRUPTION TEST; PROTEIN EXPRESSION; PSYCHOPHYSIOLOGY; RAT; SEX DIFFERENCE; TASK PERFORMANCE; WEIGHT GAIN;

ADOLESCENT; ANIMALS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; COGNITION; CYTOSKELETAL PROTEINS; DRONABINOL; EXPLORATORY BEHAVIOR; FEMALE; GENE EXPRESSION; HALLUCINOGENS; HIPPOCAMPUS; HUMANS; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAZE LEARNING; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; NEUROPEPTIDES; RATS; RATS, WISTAR; SEX FACTORS;

EID: 84892611833     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078386     Document Type: Article

References (87)

1. Cunningham JI, Raudensky J, Tonkiss J, Yamamoto BK (2009) MDMA pretreatment leads to mild chronic unpredictable stress-induced impairments in spatial learning. Behav Neurosci 123: 1076-1084.
2. Beveridge TJ, Mechan AO, Sprakes M, Pei Q, Zetterstrom TS, et al. (2004) Effect of 5-HT depletion by MDMA on hyperthermia and Arc mRNA induction in rat brain. Psychopharmacology (Berl.) 173: 346-352.
3. Parrott AC (2004) MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50: 329-335.
4. Gouzoulis-Mayfrank E, Daumann J (2009) Neurotoxicity of drugs of abuse-the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues Clin Neurosci 11: 305-317.
5. Ludwig V, Mihov Y, Schwarting RK (2008) Behavioral and neurochemical consequences of multiple MDMA administrations in the rat: role of individual differences in anxiety-related behavior. Behav Brain Res 189: 52-64.
6. Piper BJ (2007) A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). Neurotoxicol Teratol 29: 288-300.
7. Walker QD, Williams CN, Jotwani RP, Waller ST, Francis R, et al. (2007) Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats. Psychopharmacology (Berl.) 189: 435-445.
8. Quednow BB, Kühn KU, Hoppe C, Westheide J, Maier W, et al. (2007) Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy"). Psychopharmacology (Berl.) 189: 517-530.
9. Quednow BB, Jessen F, Kuhn KU, Maier W, Daum I, et al. (2006) Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J Psychopharmacol 20: 373-384.
10. EMCDDA (2011) Annual report 2011: the state of the drug problem in Europe. European Monitoring Centre for Drugs and Drug Addiction.
11. Robledo P (2010) Cannabinoids, opioids and MDMA: neuropsychological interactions related to addiction. Curr Drug Targets 11: 429-439.
12. Senn Ch, Bücheli A, Schaub M, Stohler R (2007) Club drugs. Ther Umsch 64: 109-113.
13. Malone DT, Hill MN, Rubino T (2010) Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol 160:511-522.
14. Rubino T, Parolaro D (2008) Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 286: S108-S113.
15. Rodríguez de Fonseca F, Ramos JA, Bonnin A, Fernández-Ruiz JJ (1993) Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4: 135-138.
16. Llorente-Berzal A, Fuentes S, Gagliano H, López-Gallardo M, Armario A, et al. (2011) Sex-dependent effects of maternal deprivation and adolescent cannabinoid treatment on adult rat behaviour. Addict Biol 16: 624-637.
17. Mateos B, Borcel E, Loriga R, Luesu W, Bini V, et al. (2011) Adolescent exposure to nicotine and/or the cannabinoid agonist CP 55,940 induces gender-dependent long-lasting memory impairments and changes in brain nicotinic and CB(1) cannabinoid receptors. J Psychopharmacol 25: 1676-1690.
18. Biscaia M, Marín S, Fernández B, Marco EM, Rubio M, et al. (2003) Chronic treatment with CP 55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology (Berl.) 170: 301-308.
19. Schneider M, Koch M (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28: 1760-1769.
20. Viveros MP, Llorente R, Suarez J, Llorente-Berzal A, López- Gallardo M, et al. (2012) The endocannabinoid system in critical neurodevelopmental periods: sex differences and neuropsychiatric implications. J Psychopharmacol 26: 164-176.
21. Schulz S (2011) MDMA & cannabis: a mini-review of cognitive, behavioral, and neurobiological effects of co-consumption. Curr Drug Abuse Rev 4: 81-86.
22. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J (2007) Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm 114: 959-968.
23. Wish ED, Fitzelle DB, O'Grady KE, Hsu MH, Arria AM (2006) Evidence for significant polydrug use among ecstasy-using college students. J Am Coll Health 55: 99-104.
24. Robledo P, Trigo JM, Panayi F, de la Torre R, Maldonado R (2007) Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Psychopharmacology (Berl.) 195: 255-264.
25. Young JM, McGregor IS, Mallet PE (2005) Co-administration of THC and MDMA ('ecstasy') synergistically disrupts memory in rats. Neuropsychopharmacology 30: 1475-1482.
26. Morley KC, Li KM, Hunt GE, Mallet PE, McGregor IS (2004) Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ("Ecstasy") in rats. Neuropharmacology 46: 954-965.
27. Shen EY, Ali SF, Meyer JS (2011) Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats. Neuropharmacology 61: 1183-1192.
28. Viveros MP, Marco EM, López-Gallardo M, Garcia-Segura LM, Wagner EJ (2011) Framework for sex differences in adolescent neurobiology: a focus on cannabinoids. Neurosci Biobehav Rev 35: 1740-1751.
29. Viveros MP, Llorente R, López-Gallardo M, Suarez J, Bermúdez-Silva F, et al. (2009) Sex-dependent alterations in response to maternal deprivation in rats. Psychoneuroendocrinology 34 Suppl 1: S217-S226.
30. Viveros MP, Marco EM, File SE (2006) Nicotine and cannabinoids: parallels, contrasts and interactions. Neurosci Biobehav Rev 30: 1161-1181.
31. Carroll ME, Lynch WJ, Roth ME, Morgan AD, Cosgrove KP (2004) Sex and estrogen influence drug abuse. Trends Pharmacol Sci 25: 273-279.
32. Bubeníková V, Votava M, Horácek J, Pálenícek T (2005) Relation of sex and estrous phase to deficits in prepulse inhibition of the startle response induced by ecstasy (MDMA). Behav Pharmacol 16: 127-130.
33. Palenicek T, Votava M, Bubenikova V, Horacek J (2005) Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats. Physiol Behav 86: 546-553.
34. Rubino T, Vigano D, Realini N, Guidali C, Braida D, et al. (2008) Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 33: 2760-2771.
35. Meyer JS, Piper BJ, Vancollie VE (2008) Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence. Ann NY Acad Sci 1139: 151-163.
36. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149-167.
37. Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31: 47-59.
38. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl.) 156: 117-154.
39. Rubino T, Forlani G, Viganò D, Zippel R, Parolaro D (2004) Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol Cell Neurosci 25: 355-362.
40. Di Benedetto M, Bastías Candia Sdel C, D'Addario C, Porticella EE, Cavina C, et al. (2011) Regulation of opioid gene expression in the rat brainstem by 3,4-methylenedioxymethamphetamine (MDMA): role of serotonin and involvement of CREB and ERK cascade. Naunyn Schmiedebergs Arch Pharmacol 383: 169-178.
41. Einat H, Yuan P, Gould TD, Li J, Du J, et al. (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23: 7311-7316.
42. Bramham CR, Alme MN, Bittins M, Kuipers SD, Nair RR, et al. (2010) The Arc of synaptic memory. Exp Brain Res 200: 125-140.
43. Hill MN, Tasker JG (2012) Endocannabinoid signaling, glucocorticoid- mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 204: 5-16.
44. Graham DL, Herring NR, Schaefer TL, Vorhees CV, Williams MT (2010) Glucose and corticosterone changes in developing and adult rats following exposure to (+/2)-3,4-methylendioxymethamphetamine or 5- methoxydiisopropyltryptamine. Neurotoxicol Teratol 32: 152-157.
45. Kobeissy FH, Jeung JA, Warren MW, Geier JE, Gold MS (2008) Changes in leptin, ghrelin, growth hormone and neuropeptide-Y after an acute model of MDMA and methamphetamine exposure in rats. Addict Biol 13: 15-25.
46. Cai XJ, Widdowson PS, Harrold J, Wilson S, Buckingham RE, et al. (1999) Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes 48: 2132-2137.
47. Llorente R, Arranz L, Marco EM, Moreno E, Puerto M, et al. (2007) Early maternal deprivation and neonatal single administration with a cannabinoid agonist induce long-term sex-dependent psychoimmunoendocrine effects in adolescent rats. Psychoneuroendocrinology 32: 636-650.
48. Spear LP (2000) The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24: 417-463.
49. Ozaita A, Puighermanal E, Maldonado R (2007) Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 102: 1105-1114.
50. Sim-Selley LJ (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15: 91-119.
51. Kolyaduke OV, Hughes RN (2012) Increased anxiety-related behavior in male and female adult rats following early and late adolescent exposure to 3,4-methylenedioxymethamphetamine (MDMA). Pharmacol Biochem Behav 103: 742-749.
52. Achat-Mendes C, Anderson KL, Itzhak Y (2003) Methylphenidate and MDMA exposure in mice: long-lasting consequences on cocaine-induced reward and psychomotor stimulation in adulthood. Neuropharmacology 45: 106-115.
53. Malberg JE, Seiden LS (1998) Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18: 5086-5094.
54. Taffe MA (2012) D9-Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys. Neuroscience 201: 125-133.
55. Dumont GJ, Kramers C, Sweep FC, Touw DJ, van Hasselt JG, et al. (2009) Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans. Clin Pharmacol Ther 86: 160-166.
56. Davis JF, Krause EG, Melhorn SJ, Sakai RR, Benoit SC (2009) Dominant rats are natural risk takers and display increased motivation for food reward. Neuroscience 162: 23-30.
57. Montoya AG, Sorrentino R, Lukas SE, Price BH (2002) Long-term neuropsychiatric consequences of "ectasy" (MDMA): a review. Harv Rev Psychiatry 10: 212-220.
58. Morgan MJ (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl.) 152: 230-248.
59. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen H (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68: 195-207.
60. Rubino T, Realini N, Braida D, Guidi S, Capurro V, et al. (2009) Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 19: 763-772.
61. Cha YM, Jones KH, Kuhn CM, Wilson WA, Swartzwelder HS (2007) Sex differences in the effects of D9 tetrahydrocannabinol on spatial learning in adolescent and adult rats. Behav Pharmacol 18: 563-569.
62. Craft RM, Marusich JA, Wiley JL (2012) Sex differences in cannabinoid pharmacology: A reflection of differences in the endocannabinoid system? Life Sci 92: 476-481.
63. López-Gallardo M, López-Rodríguez AB, Llorente-Berzal A, Rotllant D, Mackie K, et al. (2012) Maternal deprivation and adolescent cannabinoid exposure impact hippocampal astrocytes, CB1 receptors and brain-derived neurotrophic factor in a sexually dimorphic fashion. Neuroscience 204: 90-103.
64. Anderson BM, Rizzo M, Block RI, Pearlson GD, O'Leary DS (2010) Sex, drugs, and cognition: effects of marijuana. J Psychoactive Drugs 42: 413-424.
65. Schneider M, Schömig E, Leweke FM (2008) Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol 13: 345-357.
66. Pope HG Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, et al. (2003) Earlyonset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 69:303-310.
67. Rodsiri R, Spicer C,Green AR, Marsden CA, Fone KC (2011) Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats. Psychopharmacology (Berl.) 213: 365-376.
68. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K (1998) Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. J Psychopharmacol 12: 79-83.
69. Montgomery C, Fisk JE, Newcombe R (2005) The nature of ecstasy-group related deficits in associative learning. Psychopharmacology (Berl.) 180: 141- 149.
70. Skelton MR, Williams MT, Vorhees CV (2008) Developmental effects of 3,4-methylenedioxymethamphetamine: a review. Behav Pharmacol 19: 91-111.
71. Vollenweider FX, Remensberger S, Hell D, Geyer MA (1999) Opposite effects of3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology (Berl.) 143: 365-372.
72. Shortall SE, Macerola AE, Swaby RT, Jayson R, Korsah C, et al. (2012) Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol In Press
73. Wegener N, Koch M (2009) Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res 1253: 81-91.
74. Sher KJ, Bartholow BD, Wood MD (2000) Personality and substance use disorders: a prospective study. J Consult Clin Psychol 68: 818-829.
75. Nash JF Jr, Meltzer HY, Gudelsky GA (1988) Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 245: 873-879.
76. Baumann MH, Wang X, Rothman RB (2007) 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl.) 189: 407-424.
77. Gerra G, Bassignana S, Zaimovic A, Moi G, Bussandri M, et al. (2003) Hypothalamic-pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine ('ecstasy') use history: correlation with dopamine receptor sensitivity. Psychiatry Res 120: 115-124.
78. Llorente R, Miguel-Blanco C, Aisa B, Lachize S, Borcel E, et al. (2011) Long term sex-dependent psychoneuroendocrine effects of maternal deprivation and juvenile unpredictable stress in rats. J Neuroendocrinol 23: 329-344.
79. Korb E, Finkbeiner S (2011) Arc in synaptic plasticity: from gene to behavior. Trends Neurosci 34: 591-598.
80. Bramham CR, Worley PF, Moore MJ, Guzowski JF (2008) The immediate early gene arc/arg3.1: regulation, mechanisms, and function. J Neurosci 28: 11760-11767.
81. Guzowski JF, Lyford GL, Stevenson GD, Houston FP, McGaugh JL, et al. (2000) Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J Neurosci 20: 3993-4001.
82. Lebesgue D, Chevaleyre V, Zukin RS, Etgen AM (2009) Estradiol rescues neurons from global ischemia-induced cell death: multiple cellular pathways of neuroprotection. Steroids 74: 555-561.
83. Wittmann G, Deli L, Kallo I, Hrabovszky E, Watanabe M, et al. (2007) Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus. J Comp Neurol 503:270-279.
84. Acuna-Goycolea C, Obrietan K, van den Pol AN (2010). Cannabinoids excite circadian clock neurons. J Neurosci 30: 10061-10066.
85. Rao Y, Mineur YS, Gan G, Wang AH, Liu ZW, et al. (2013) Repeated in vivo exposure of cocaine induces long-lasting synaptic plasticity in hypocretin/orexin-producing neurons in the lateral hypothalamus in mice. J Physiol 591: 1951-1966.
86. McLusky NJ, Naftolin F (1981) Sexual differentiation of the central nervous system. Science 211: 1294-1303.
87. Allott K, Redman J (2007) Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)? Neurosci Biobehav Rev 31: 327-347.